Kan Chen

Dr. Chen is primarily responsible for participating in formulating the Company’s corporate and business strategies.

Dr. Chen is currently serving as a Principal at Qiming Venture Partners (“Qiming”), focusing on healthcare investment. Dr. Chen joined Qiming in February 2016, had served as associate and vice president, and was deeply involved in Qiming’s investment of the Company’s Series A financing. Dr. Chen has been a director of Connect Biopharma Holdings Limited (Nasdaq: CNTB) since December 2020. From November 2012 to September 2014, Dr. Chen has been the group leader of Jiangsu Hengrui Medicine Co., Ltd. From October 2014 to January 2016, he has been the senior scientist of Janssen, Pharmaceutical Companies of Johnson & Johnson.

Dr. Chen obtained his bachelor’s degree in biological science from Fudan University in June 2004. He obtained his Doctor of Philosophy degree in cell biology from Case Western Reserve University in January 2009 and finished his postdoctoral training in immunology at Harvard Medical School in October 2012.